Drug
Risperidone ISM® 100 mg
Risperidone ISM® 100 mg is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Phase Distribution
Ph phase_3
2
40%
Ph phase_1
3
60%
Phase Distribution
3
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 3Large-scale testing
2(40.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 13 (60.0%)
Phase 32 (40.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths
NCT01788774
completedphase_3
Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
NCT03870880
completedphase_3
Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia
NCT03160521
completedphase_1
Comparative Bioavailability of Risperidone.
NCT05179525
completedphase_1
Comparative Bioavailability of Risperidone
NCT03527186
Clinical Trials (5)
Showing 5 of 5 trials
NCT01788774Phase 1
Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths
NCT03870880Phase 3
Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
NCT03160521Phase 3
Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia
NCT05179525Phase 1
Comparative Bioavailability of Risperidone.
NCT03527186Phase 1
Comparative Bioavailability of Risperidone
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5